1 study on RHO-TARGET-1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research represents a significant advancement by identifying a novel class of macrocyclic peptides that specifically target the oncogenic RhoA G17V mutation. The high specificity and potent in vitro inhibitory ac…